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Abstract The analysis of cerebrospinal fluid (CSF) bio-
markers gains importance in the differential diagnosis of prion
diseases. However, no single diagnostic tool or combination
of them can unequivocally confirm prion disease diagnosis.
Electrochemiluminescence (ECL)-based immunoassays have
demonstrated to achieve high diagnostic accuracy in a variety
of sample types due to their high sensitivity and dynamic
range. Quantification of CSF α-synuclein (a-syn) by an in-
house ECL-based ELISA assay has been recently reported
as an excellent approach for the diagnosis of sporadic
Creutzfeldt-Jakob disease (sCJD), the most prevalent form
of human prion disease. In the present study, we validated a
commercially available ECL-based a-syn ELISA platform as
a diagnostic test for correct classification of sCJD cases. CSF
a-syn was analysed in 203 sCJD cases with definite diagnosis
and in 445 non-CJD cases. We investigated reproducibility
and stability of CSF a-syn and made recommendations for
its analysis in the sCJD diagnostic workup. A sensitivity of
98% and a specificity of 97% were achieved when using an
optimal cut-off of 820 pg/mL a-syn. Moreover, we were able
to show a negative correlation between a-syn levels and dis-
ease duration suggesting that CSF a-syn may be a good prog-
nostic marker for sCJD patients. The present study validates
the use of a-syn as a CSF biomarker of sCJD and establishes
the clinical and pre-analytical parameters for its use in differ-
ential diagnosis in clinical routine. Additionally, the current
test presents some advantages compared to other diagnostic
approaches: it is fast, economic, requires minimal amount of
CSF and a-syn levels are stable along disease progression.
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Creutzfeldt-Jakob disease (CJD) is the most common human
prion disease characterised by the accumulation of patholog-
ical misfolded prion protein (PrPSc) in the central nervous
tissue.Most patients present an unknown aetiology being clas-
sified as sporadic Creutzfeldt-Jakob disease (sCJD), which is
clinically characterised by the presence of dementia and ataxia
[1, 2]. sCJD affects 1 to 2 per 1,000,000 individuals per year
[3], and it is invariably fatal, usually within 1 year from dis-
ease onset [1]. Therefore, biomarkers able to discriminate
sCJD from other neurological and neurodegenerative condi-
tions with similar clinical presentation are required [4, 5]. This
is of special importance in the differential diagnostics from
alternative forms of rapidly progressive dementias with avail-
able treatment to generate an appropriate therapeutic interven-
tion before pathological changes spread throughout the brain
[6]. Established CSF biomarkers for sCJD tested in clinical
workup in suspected cases are 14-3-3 and total tau (tau). A
major limitation of these biomarkers results from the occur-
rence of their increased levels in acute neurologic disorders
and neurodegenerative diseases [7–13]. The clinical diagnosis
of sCJD is also supported by the real-time quaking-induced
conversion (RT-QuIC) protein aggregation assay, which ex-
hibit a high specificity, and sensitivity similar to the best sur-
rogate biomarkers in detecting sCJD cases [14–17]. However,
RT-QuIC presents increased costs, and less inter-laboratory
standardisation data is available compared to classical ap-
proaches, preventing its widespread implementation in clini-
cal routine.
In this context, electrochemiluminescence-based systems
have demonstrated high accuracy, reproducibility, recovery
rates and broad dynamic range in the detection of several
biomarkers in biological fluids [18, 19]. Besides its methodo-
logical upgrade compared to classical colorimetric platforms,
t h e a n a l y t i c a l a n d c l i n i c a l p e r f o rm a n c e o f
electrochemiluminescence technology in the cerebrospinal
fluid (CSF) has not been explored in detail in the differential
diagnosis of neurodegenerative dementias.
The detection of elevated α-synuclein (a-syn) in the
CSF of sCJD cases using colorimetric assays was previ-
ously reported [20, 21]. However, the differences between
sCJD and control groups were rather limited, and the ac-
curacy of the tests was low. Recently, we reported that the
use of an in-house a-syn electrochemiluminescence-based
enzyme-linked immunosorbent assay (ELISA) platform
presented high accuracy in the discrimination of sCJD
cases [19, 22]. However, the implementation of CSF a-
syn measurements in diagnostic routine of sCJD would
get benefit of the validation and establishment of diagnos-
tic accuracy in a commercially available platform, facilitat-
ing its technical implementation and inter-laboratory
standardisation.
In the present study, we analysed a commercial
electrochemiluminescence-based human a-syn ELISA kit as
a novel test method in sCJD diagnosis. The present test
allowed discriminating non-CJD from sCJD cases with high
diagnostic accuracy. Importantly, data were collected from
three independent cohorts of sCJD autopsy-confirmed cases.
Since standard protocols and sample handling have become
more important in routine diagnostic, recommendations for
the CSF a-syn diagnostic of sCJD are reported based on the




The study included a total of 648 patients recruited at the
National Reference Center for Transmissible Spongiform
Encephalopathies of the Department of Neurology and
Neuropathology at the University Medical Center of
Gottingen, Germany (cohort 1), at Polish neurologic and psy-
chiatric hospital departments (cohort 2) and at the Unit of Bio-
diagnostic of CJD and other prion diseases at the Hospital
Clinical of Barcelona, Spain (cohort 3). All patients with
sCJD were classified as definite cases by neuropathological
examination according to diagnostic consensus criteria [23].
Non-CJD cases were composed of patients referred to the
same centres where prion disease diagnosis was excluded ac-
cording to clinical criteria or autopsy. Non-CJD cases includ-
ed the following: neurologically healthy patients (no neuro-
logical clinical diagnosis and normal neuro-physicological as-
sessment) (n = 41) and patients suffering from neurological
diseases (n = 149) or neurodegenerative conditions and cog-
nitive impairment/dementia (n = 255). Neurological diseases
included psychiatric disorders (psychosis, bipolar disorder,
depression and schizophrenia), ischemic stroke, epilepsy, au-
toimmune diseases, meningitis, alcohol abuse, headache, ver-
tigo, pain syndromes, acute hypoxia, encephalopathy, cerebral
vasculitis, normal pressure hydrocephalus and alternative neu-
rologic conditions. Neurodegenerative disease included
Parkinson’s disease, dementia with Lewy bodies, multiple
system atrophy, Alzheimer’s disease, frontotemporal demen-
tia, Huntington’s disease, vascular dementia, corticobasal de-
genera t ion , progress ive supranuclear pa lsy and
olivopontocerebellar atrophy.
CSF samples were tested for blood contamination using
Hemastix strips (Siemens), and cases containing more than
25 erythrocytes/mm3 and/or haemoglobin contamination were
intentionally excluded from this study in order to avoid pos-
sible false positive outcomes. Information about demo-
graphics and CSF biomarkers tau and 14-3-3 of the study
population are supplied in Table 1.
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Statistical Methods
Mann-Whitney U tests were used to compare two groups
of samples. For analysis of a-syn stability, Wilcoxon
signed rank sum tests were applied. In order to assess
the diagnostic accuracy of a-syn, receiver operating char-
acteristic (ROC) curve analyses were carried out and
areas under the curve (AUC) with 95% confidence inter-
vals were calculated using GraphPad Prism 6.01. The
best cut-off value was estimated based on the Youden
index [24] derived from cohorts 2 and 3 and was then
externally validated in cohort 1. To compare the sensi-
tivities between biomarkers, the McNemar’s test was
used. Spearman rank correlation was used to test associ-
ation between biomarker levels. For codon 129 polymor-
phism comparison, cases were tested for normality, and
Kruskal-Wallis test followed by Dunns post-test was ap-
plied. In order to determine the effect of a-syn levels on
clinical outcome, the association between a-syn levels
and total disease duration (time between disease onset
and death) was assessed using a fractional polynomial
approach.
CSFAnalysis
Quantification of a-syn was performed using the
electrochemiluminescence-based ELISA-based human a-syn
kit from Meso Scale Discovery (MSD) (Catalogue No.
K151TGD) following manufacturer’s instructions. Briefly, as-
say plates were blocked by adding 150 μl of Diluent 35 to
each well. Plates were sealed and incubated at room tempera-
ture with shaking at 300 rpm for 1 h. Then, plates were washed
three times with 150 μl per well of PBS-T (PBS supplemented
with 0.05% Tween-20). Detection antibody (25 μl) and CSF
(diluted 1:8) or calibrator (25 μl) was added to each well.
Plates were sealed and incubated at room temperature with
shaking at 700 rpm for 2 h. After washing as indicated above,
150 μl of 2× read buffer T was added to each well.
Measurements were performed on a MSD Sector Imager
6000. Calibrators were run in duplicate to generate calibration
curve.
Tau was quantified using the INNOTESThTAU-Ag
(Fujirebio, Gent, Belgium) ELISA test. 14-3-3 was semi-
quantitatively tested by using Western blot as previously de-
scribed [8].
Analysis of a-syn Stability
To evaluate the effects of CSF storage conditions (temperature
and freezing/thawing cycles) on a-syn concentration, CSF
samples from 8 sCJD patients were stored in polypropylene
tubes at room temperature and 4 °C for 1, 3 and 6 days. In
addition, CSF samples were subjected to 2, 4 and 8 repeated
freezing and thawing cycles. a-syn concentrations at each time
point or cycle were calculated as percent of control (time point
zero), which was defined as 100%.
Ethics
The study was conducted according to the revised Declaration
of Helsinki and Good Clinical Practice guidelines and ap-
proved by local Ethics committees Goettingen (No. 9/6/08,
19/11/09, 18/8/15). Informed consent was given by all study
participants or their legal next of kin.
Results
ELISATest Performance in the Quantification of CSF
a-syn Quantification
CSF a-syn levels were measured using the electrochemilu
]minescence-based human a-syn kit (Fig. 1a). The dynamic
range of the assay was from 1.52 ± 0.42 to 10,000 pg/mL a-
syn. The precision of the assay was validated by the low co-
efficients of variation (CV) measured in separate runs,
Table 1 Demographic characteristics of the study population analysed
and CSF prion biomarker data
a
Demographics non-CJD sCJD
Number of cases 445 203
Age (mean ± SD (years)) 66 ± 12 66 ± 9
Gender (w/m in %) 54/46 52/48
sCJD biomarkers
14-3-3 (p─w─n in %) 12─2─84 91─2─7
tau (mean ± SD (pg/mL)) 402 ± 376 5965 ± 4911
b
α -synuclein (pg/mL) non-CJD sCJD
Mean 324 8906
Standard deviation 214 7790
Standard error 10 548
Minimum 70 513
25% percentile 200 3183
Median 259 6595
75% percentile 364 11,950
Maximum 1908 41,960
Lower 95% CI 304 7828
Upper 95% CI 344 9984
a. The total number of cases, age (mean ± SD in years) and gender
distribution as well as tau (mean ± SD in pg/mL) and 14-3-3 semi-
quantification (% of positive (p), weak/inconclusive (w) and negative
(n)) is reported. b. CSF a-syn levels (in pg/mL) in non-CJD and sCJD
cases. Mean values, standard deviation and standard error, percentile
values and lower and upper 95% CI are indicated
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samples, laboratories and analysers as suggested elsewhere
[25]. In all cases, repeatability and within-lab/plate reproduc-
ibility were below 9% (Fig. 1b), validating precision and
limits of quantification of the assay. Inter-lot and inter-
laboratory variability were lower than 11 and 12%, respective-
ly. Dilution linearity was assessed in serial dilutions of CSF to
avoid hook effect. Selected CSF dilution (1:8) permitted the
lineal quantification of the lowest and highest a-syn levels
without the need to analyse multiple sample dilutions.
Diagnostic Accuracy of CSF a-syn as sCJD Biomarker
Our study cohort included a total of 445 non-CJD and 203
sCJD cases. CSF a-syn showed an excellent accuracy in dis-
criminating non-CJD from sCJD cases (p < 0.001 and
AUC = 0.997, 95% CI: 0.995 to 0.999) (Fig. 2a, b). Mean a-
syn values were 324 ± 214 in non-CJD and 8906 ± 7790 in
sCJD (Table 1b). Using a cut-off of 820 pg/mL of a-syn (op-
timal level identified by Youden index in the training cohorts),
a sensitivity of 98% (95% CI: 93–99%) and a specificity of
97% (95%CI: 95–99%) was achieved in the validation cohort
(Fig. 2b). Since high sensitivities are reported for CSF 14-3-3
and tau tests in the detection of sCJD cases [7–13, 26, 27]
(Supplementary Table 2), we aimed to compare the perfor-
mance of the three biomarkers in the same population. 14-3-
3 and tau from cohort 1 (n = 128) presented sensitivities of 91




Fig. 2 Diagnostic accuracy of CSF a-syn levels as sCJD biomarker. a
CSF a-syn levels in non-sCJD and sCJD. Statistically significant
differences were detected between non-CJD and sCJD cases
(p < 0.001). b ROC curve for a-syn in the comparative analysis
between non-sCJD cases and sCJD cases. Sensitivity and specificity,
receiver operating characteristic (ROC) curves and derived area under
the curve (AUC) were calculated. Based on Youden Index, an optimal
cut-off of 820 pg/mL a-syn and a sensitivity of 98% and specificity of






Fig. 1 Quantification of CSF a-syn by the human ELISA kit fromMSD.
a Representative plot for quantification of CSF a-syn in samples from
CJD and non-CJD cases. The dynamic range is indicated in blue.
Calibrators are denoted as blue spots and unknown samples as red
spots. CSF samples from diverse aetiology were in detection range
using a 1:8 dilution. b Analytical and technical parameters derived from
quantification of CSF a-syn with the human ELISA kit from MSD are
shown
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and 92%, respectively, in detecting sCJD cases, which was
significantly lower than those obtained for CSF a-syn (98%).
Neither a specific diagnostic group nor a correlation between
a-syn and tau/14-3-3 profile was detected in the non-CJD
cases tested positive for a-syn. Comparison of sensitivities in
cohort 1 between the three biomarkers revealed statistical dif-
ferences between a-syn vs tau (p = 0.035) and a-syn vs 14-3-3
(p = 0.021) comparisons, but not in tau vs 14-3-3 (p = 0.763).
Additionally, we found a positive correlation between CSF a-
syn and tau levels (p < 0.001) in control subjects and in sCJD
cases, in agreement with the observations from our previous
study [22]. Next, we investigated the role of PRNP codon 129
polymorphism on CSF a-syn levels. Information about codon
polymorphism was available for 182 cases (MM = 120,
MV = 23 and VV = 34). As we previously reported [22], a-
syn levels in MV cases (5391 ± 4780 pg/mL a-syn) were
s ign i f ican t ly lower than those de tec ted in MM
(9695 ± 7605 pg/mL a-syn) (p < 0.05). Mean values in MV
cases were also lower than in VV (9941 ± 9733 pg/mL a-syn).
However, these differences were not statistically significant.
Influence of Timing in CSF Tests and of Disease Duration
Next, we assessed the influence of time of CSF sampling on a-
syn concentration in the diagnosis of sCJD. For this, samples
from 10 sCJD patients for which CSF at different stages of
disease was available were tested. Since disease duration in
sCJD is highly variable, depending on demographic and ge-
netic characteristics [2], the time interval between disease on-
set and lumbar puncture (LP) is not an appropriate estimate of
the stage of disease when the LP was performed. Instead, we
divided the time of LP to disease onset in each patient by the
total duration of the disease. Then, samples were grouped in
three categories according to whether they underwent LP in
the first (time of LP to disease onset/total duration of the
disease <0.33), second (0.33–0.66), or third (>0.66) stage of
the disease, as previously reported [28]. No major alterations
in CSF a-syn concentration were detected between different
LPs in nine of the cases (Fig. 3a). One case presented a de-
crease in a-syn levels, most likely related to its rapid disease
course (3 weeks from disease onset to death).
CSF a-syn levels were inversely associated with disease
duration (p < 0.001) in the 185 cases where disease duration
was known (Fig. 3b). This suggests a role for CSF a-syn as a
prognostic sCJD marker. In this regard, our data indicate that
when a-syn levels are higher than 20,000 pg/mL, disease du-
ration was inevitably shorter than 1 year. By using fractional
polynomial linear regression analysis, the expected duration
of disease from the a-syn value can be estimated by using the
following equation: duration in months = 5.70 + 1.43*((a-syn
(pg/mL)/10,000)−0.5–0.99)–0.57*((a-syn (pg/mL)/10,000)–
1.02).
Effect of Multiple Freeze/Thaw Cycles and Defined
Storage Conditions
Storage of CSF at room temperature or at 4 °C for up to
6 days had no effect on a-syn concentration (Fig. 4a, b).
CSF a-syn was stable for up to four freezing/thawing
cycles while a decrease of 9.7 ± 6.7% (p < 0.05) was
detected after 8 cycles (Fig. 4c). Additionally, CSF stor-
age for 12 months at −80 °C did not alter the levels of




Fig. 3 Influence of timing and disease duration in CSF a-syn levels. a
CSF a-syn levels in serial LPs in sCJD cases at different stages of the
disease. Samples were grouped in three categories according to whether
they underwent LP in the first (time from disease onset to LP/total
duration of the disease <0.33), second (0.33–0.66) or third (>0.66)
stage of the disease. Dashed line indicates established cut-off for sCJD.
bAssociation between CSF a-syn levels and disease duration (months) in
sCJD patients analysed by a fractional polynomial linear regression
approach (p < 0.001). Displayed is the functional form of the
association with 95% confidence intervals. The expected duration of
disease can be estimated by using the following equation: duration in




CSF a-syn quantification by an in-house electrochemilu
minescence-based ELISA platform has been recently reported
as a useful biomarker in the discrimination of sCJD cases from
a broad range of neurological and neurodegenerative disorders
[22]. However, implementation of the assay in clinical diag-
nostics requires the following: (i) the validation and
standardisation of a commercially available kit, along with
definition of diagnostic accuracy and cut-off values, and (ii)
investigation of relevant pre-analytical parameters to be con-
sidered for sample collection and management. In the present
study, the human a-syn kit from Meso Scale Discovery® has
been validated as a diagnostic test for sCJD. Clinical accuracy
has been established, and pre-analytical parameters for appro-
priate sample handling are reported. The ELISA kit showed
high reproducibility (intra- and inter-assays <9%) and sensi-
tivity and a broad dynamic range. The wide dynamic range of
the detection system (4 logs) allowed the quantification of a-
syn levels without the need of multiple sample dilutions.
Because of the high sensitivity of the technology, lower
amounts of CSF are required compared to other approaches.
Other advantages of the present system include its low back-
ground since stimulation method (electricity) is coupled to the
signal (light) allowing only labels near the electrode surface to
be detected.
In the study of the accuracy of a-syn levels as sCJD bio-
marker, we analysed one of the largest studied cohorts with
definite prion disease. At the optimal cut-off of 820 pg/mL a-
syn, we obtained a specificity of 98% and a sensitivity of 97%
in the validation cohort. Importantly, biomarker cut-off was
externally validated in an independent cohort from a different
country, underlining the relevance of the findings.
Overall, a-syn test shows an optimal diagnostic accuracy in
the specific detection of sCJD cases, with clinical parameters
in the range of the best currently available prion biomarkers
(Supplementary Table 2) such as p-tau/tau ratio [29] and the
newly implemented real-time quaking-induced conversion
RT-QuIC [15]. Additionally, the present ELISA tests
displayed a similar analytical performance as previously re-
ported for an in-house electrochemiluminescence-based
ELISA platform [22], reinforcing the robustness of the
method.
Several CSF biomarkers are currently used as valuable
tools for the diagnosis of sCJD. While most of them are sur-
rogate disease markers (14-3-3, tau, S100B, NSE) [7], RT-
QuIC directly measures the amount of pathogenic prion
*
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Fig. 4 Effect of short- and long-term storage on CSF a-syn concentration
in sCJD patients. CSF a-syn levels were determined as indicated in
BMaterial and Methods^. CSF a-syn concentration is shown relative to
the reference sample (time point 0), which was set as 100%. The
concentration of CSF a-syn from 8 different sCJD patients (n = 8) was
determined a before and after storage at room temperature (0 to 6 days), b
storage at 4 °C (0 to 6 days) and c after repeated freezing and thawing
cycles (0 to 8 cycles). A significant loss of CSF a-syn level could be
observed in samples subjected to 8 freezing-thawing cycles. Error bars
represent standard deviations (SD)
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protein able to induce the conversion of recombinant PrP mol-
ecules in a fluorimetric seeding assay [15–17]. Surrogate
markers with highest sensitivity such as 14-3-3 and tau present
lower specificity when tested on several neurological condi-
tions [7, 29, 30]. Indeed, positive 14-3-3 signal can be detect-
ed in the CSF of various neurological disorders such as acute
stroke, meningoencephalitis, and subarachnoidal haemor-
rhage [31, 32], while elevated tau is a common hallmark in
several types of neurodegenerative dementias (Alzheimer’s
disease, mild cognitive impairment, vascular dementia, and
fronto-temporal dementia) [29, 33] and in acute ischemic
events [34]. On the contrary, elevated a-syn is not detectable
in any group of neurological and neurodegenerative disorders
as reported before [22], and in the present study, enhancing the
specificity of the test over other biomarker approaches. In this
regard, RT-QuIC overcomes the handicap of surrogate bio-
markers regarding specificity; however, sensitivity is still not
optimal as shown in several other studies (85–96%) [16].
Furthermore, a-syn measurement is faster (3.5 h) than for first
and second generation RT-QuIC assays (<2 days and 4–14 h,
respectively) [15, 17]. Regarding pre-analytical conditions,
some inconsistencies are reported in the bibliography.
Regarding pre-analytical conditions, some inconsistencies
are reported in the bibliography. While CSF a-syn levels were
found to be decreased after 4 days at 4 °C and 6 freeze/thaw
cycles [35], Kruse et al., in agreement with our observations,
showed a great stability on a-syn levels on a broad range of
pre-analytical conditions, including freeze/thawing cycles and
temperature storage conditions [36]. A limitation of CSF a-
syn quantification is the increased abundance of a-syn in pe-
ripheral blood [37]; thus, CSF samples must be tested for
blood contamination in relation to this test. Indeed, presence
of blood contamination is usually tested in prion diagnosis
routine due to its influence in other CSF biomarkers such as
14-3-3 and RT-QuIC [17, 27]. Although new generation
ELISA platforms are not yet implemented in most clinical
routine laboratories, their reported technical advantages over
classical colorimetric systems and the possibility to simulta-
neously test different analytes in a single run will help to
increase its widespread implementation in dementia diagnos-
tic work up.
sCJD disease duration varies depending on demographic
and genetic factors from several weeks to 3 years [3], with an
average disease duration of 5 months, and only 14% of the
patients surviving longer than 1 year (Creutzfeldt-Jakob
Disease International Surveillance Network, http://www.
eurocjd.ed.ac.uk). Here, we also demonstrated that CSF a-
syn levels are stable along disease duration as reported in a
group of sCJD cases ranging from the lowest to the highest a-
syn levels for which serial LPs were available. Altogether, our
study supports the use of CSF a-syn quantification in diagnos-
tic routine as a first robust, cheap and fast discriminatory assay
to detect sCJD cases, which could be further validated by
means of RT-QuIC test to achieve a defined pre-mortem
diagnosis.
We summarised the outcome of our study and prepared a
recommendation table for pre-analytical sample handling and
storage to improve standardisation of CSF a-syn quantifica-
tion for the diagnosis of sCJD patients in clinical routine
(Table 2). See also recommendations for sample handling
published recently [35].
A potential further application of CSF a-syn quantification
is its use as prognostic marker, since disease duration showed
a negative correlation with a-syn levels, comparable to CSF
tau [38]. In this regard, a valuable outcome of our work is the
presentation of an equation to estimate the expected duration
of disease from the a-syn value. Indeed, identification of ge-
netic, demographic and biochemical predictors of survival
time is of crucial interest, not only for diagnosis and counsel-
ling, but also for the correct assessment and evaluation of an
eventual therapeutic intervention.
a-syn, α-synuclein; AUC, area under the curve; CJD,
Creutzfeldt-Jakob disease; ECL, Electrochemiluminescence;
ELISA, enzyme-linked immunosorbent assay; LP, lumbar
puncture; CSF, cerebrospinal fluid; PrPSc, pathological
misfolded prion protein; ROC, receiver operating characteris-
tic; RT-QuIC, real-time quaking-induced conversion; sCJD,
sporadic Creutzfeldt-Jakob disease; SD, standard deviation.
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Table 2 Recommendations for standardisation and pre-analytical
treatment of CSF samples for the analysis of a-syn in sCJD diagnostics
1 Tube selection Polypropylene tubes
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3. Shipping time Up to 6 days at 4 °C or room temperature
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Assessment for blood contamination inspection
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Freeze at −80 °C until test is performed
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6. Long-term storage Stable for at least 12 months at −80 °C
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